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obesity directly, but a corresponding decrease in resources used to treat co-mor-
bidities.
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OBJECTIVES: Obesity has reached epidemic proportions and has many cost impli-
cations. Being overweight and obese is associated with higher rates of many
chronic health conditions, which in turn leads to increases in medical spending
and productivity losses. Many worksites have implemented weight management
programs for employees to offset the cost burden of disease. This study modeled
the potential cost savings for an employer from a 2-year worksite weight manage-
ment program over ten year time horizon. METHODS: We used data from a group
randomized control trial of a worksite weight management program and published
healthcare utilization data to model long term net costs. Using a Markov decision
analytic modeling technique, we conducted a cost benefit analysis of weight man-
agement program versus usual practice. Program costs, health care utilization and
prevalence of overweight and obesity in the study population were used to assess
program impact. Sensitivity analyses were conducted to find a threshold at which
the intervention would have a positive net benefit. RESULTS: The study population
showed had a 1.44% decrease in the overweight/obesity in one year. When modeled
over 10 years, this program incurred an excess cost of $206 per person compared to
usual practice. The threshold at which this program would have a positive net
benefit is when there is a 5.8% decrease in the overweight/obese population
annually. CONCLUSIONS: Worksite weight management programs may yield cost
savings with modest reduction in the percentage of overweight or obese employ-
ees. This evidence may encourage employers to implement and support weight
management programs that have empirically demonstrated higher rates of weight
loss in employees. More research is needed to understand why some individuals
are more successful at weight reduction and to evaluate long-term effectiveness of
weight management at worksites.
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OBJECTIVES: Romiplostim stimulates platelet production via the thrombopoetin-
receptor and is recommended for second- and third-line treatment of chronic ITP
in adults. Traditional treatment options in this setting have included unapproved
use of the immunosuppressant rituximab. This analysis assessed the cost per re-
sponder of romiplostim compared to rituximab in adult ITP patients in France.
METHODS: A decision analytic model was developed to estimate the six-month
cost per patient responding to treatment. A systematic literature review was per-
formed to obtain response rates (achieving a platelet count 50x109/L) for each
treatment. Romiplostim patients received weekly administrations; rituximab pa-
tients received 4 weekly intravenous infusions. Resource utilization was based on
French and international treatment guidelines, and clinical expert opinion. Unit
costs were derived from published literature and French reimbursement lists, and
included the costs of routine physician visits, treatment administration and emer-
gency care. Non-responders incurred the cost of rescue therapy (IVIg and predni-
sone) and hospitalizations/physician visits associated with bleeding-related
events (BREs). RESULTS:Although the comparability of existing literature for romi-
plostim and rituximab was limited, several fulfilled the literature review selection
criteria. Response rates were 83% and 62.5%, as per the romiplostim pivotal trial
and a meta-analysis on rituximab, respectively. Mean cost per patient for romi-
plostim and rituximab was €17,486 and €17,086 respectively. Dividing mean cost
per patient by response rates, cost per response was €27,337 for romiplostim and
€25,178 for rituximab. The main cost-offsets were due to reduced rescue therapy
and BREs, with romiplostim resulting in a 23% reduction in cost per platelet re-
sponse. Across sensitivity analyses, romiplostim consistently produced a lower
cost per response.CONCLUSIONS: In adult ITP patients, romiplostim yields a lower
cost per response over 6 months compared to rituximab, indicating romiplostim
represents an efficient use of resources for the French health care system.
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OBJECTIVES: Continuous wound infiltration (CWI), intravenous patient controlled
analgesia (iv-PCA) and epidural analgesia (EDA) are analgesic techniques com-
monly used for pain relief after open abdominal surgery. The aim of this study was
to evaluate the cost-impact and cost-effectiveness of these analgesic techniques.
METHODS: A decision tree model was developed in which patients entered after
successful colorectal surgery and received post-operative analgesia. The pathways
consist of a number of particular events including patient eligibility given their
agreement to benefit from the technique, rate of intra-operative technical failure,
successful pain relief and potential adverse events. Data was retrieved from clini-
cal trials and from an observational prospective cohort of 85 patients. Efficacy
criteria were based on pain at mobilisation. Healthcare resource use and costs were
evaluated from medical records measurements and published data. The incremen-
tal cost-effectiveness ratio (ICER) was expressed as the ratio between differential
total cost of procedures and differential efficacy. Probabilistic sensitivity analysis
(PSA) was performed around the willingness to pay per controlled patient.
RESULTS: When taking into account all the healthcare resources consumed, the
CWI arm (€4,044) is economically dominant compared to iv-PCA (€4,779). EDA is
more costly, but also more effective than CWI, with an estimated ICER of €27,446 for
each additional controlled patient. PSA analysis shows that CWI remains cost-
saving in 71.3% of cases. CONCLUSIONS:Device-related costs of using CWI for pain
management after abdominal laparotomy are partly counterbalanced by a reduc-
tion in healthcare resource consumption. It is also important to consider that a
proportion of patients do not have the capacity to benefit from epidural techniques
and some may also refuse the technique. This economic evaluation may be useful
for clinicians to design algorithms for pain management after major abdominal
surgery.
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OBJECTIVES: About 5% of the population (400,000 in Austria) suffer from neuro-
pathic pain. Fifty percent of them denominate their pain as “very strong”. Neuro-
pathic pain patients consult on average 5 different doctors before the main diag-
nosis is found. The aim of this study was to evaluate the cost-effectiveness of
treatment of neuropathic pain with topical Capsaicin Patch 8% versus current stan-
dard of care (pregabalin) in Austria. METHODS: The analysis was performed using
a Decision Tree Model combined with a Markov model adapted for Austria. The
model is based on an indirect comparison, which results in a conservative estima-
tion, as the efficacy of capsaicin patch 8% is underestimated due to a large placebo
effect. Efficacy assessment was based on the outcome measure QALY. Costs were
captured for the year 2011. Resource use was determined by literature research and
expert opinion and accurately reflects the Austrian treatment path. The study time
horizon was 5 years. The analysis was performed from the perspective of social
health insurance. The analysis was conducted according to Austrian Guidelines for
Health Economic Evaluations. RESULTS: The results are shown for a time horizon
of 5 years. The cost per patient (30% pain reduction) for capsaicin patch 8% amount
to €4898 for a time horizon of 5 years and to €4745 for Pregabalin. Treatment with
capsaicin patch 8% leads to 3.011 QALYs, treatment with Pregabalin to 2.964 QALYs.
The cost per QALY is €1627 (capsaicin patch 8%) versus €1611 (Pregabalin) with an
ICER of €2358. CONCLUSIONS: In Austria, the treatment of neuropathic pain with
Capsaicin Patch 8% is a cost-effective alternative compared to Pregabalin from the
perspective of the social health insurance.
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OBJECTIVES: Postoperative pain is one of the main adverse outcomes causing dis-
tress to patients after cesarean delivery. Meanwhile the main analgesic drugs are
opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), more over side effects
such as nausea, vomiting, sedation were reported with opioids. METHODS: This
study was undertaken based on our clinical trial that evaluated postoperative pain
in a double-blinded, randomized, single-dose comparison of Tramadol IM injec-
tion, 100 mg (Group T) and Diclophenac suppository, 100 mg (Group D) given alone-
single dose in 100 patients who had elective cesarean delivery. All patients were
assessed at 0, 6, 12 and 24 hours post operation for pain degree (by Visual Analogue
Score: VAS 1-10), nausea and vomiting. Our outcomes were the reduction in pain.
For the cost estimates of therapeutic schemes, we computed the direct costs of the
analgesics (unitary cost) and disposable material (needles, syringes, padcol). Cost-
Effectiveness Ratio was calculated. RESULTS: The efficacy of Tramadol and Diclo-
phenac were not different significantly (P0.06). Nausea and vomiting were mini-
mal with all treatments. Total costs in T group were $52.38 and in D group were
$161.90. Cost-Effectiveness Ratio of Tramadol to Diclophenac was 2.76.
CONCLUSIONS: Cost-Effectiveness Ratio showed that the cost of Tramadol in this
study was 2.76 times more than Diclophenac with the same efficacy, thus the
analgesic effect of Diclophenac is more cost-effective than Tramadol.
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OBJECTIVES: To assess the cost effectiveness of tapentadol PR compared with
oxycodone CR for the treatment of patients with chronic severe non-cancer pain in
Ireland.METHODS:A Markov model was developed to assess the costs and benefits
of tapentadol PR and oxycodone CR treatment over a 1 year time horizon from the
Health Service Executive perspective (GMS and DP/LTI Scheme). Patients tolerating
the treatment or having mild adverse events remained on tapentadol or oxy-
codone. Patients who were lacking efficacy or had poor tolerability switched to
either transdermal fentanyl or morphine. 3rd line therapy was defined as absorb-
ing state. Data regarding efficacy, tolerability and utility values (EQ-5D) were de-
A415V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
